

Mark Slee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9251449/publications.pdf>

Version: 2024-02-01

86
papers

6,162
citations

109264

35
h-index

71651

76
g-index

91
all docs

91
docs citations

91
times ranked

8330
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360. | 9.4 | 1,213 |
| 2 | Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. <i>Nature Genetics</i> , 2009, 41, 824-828. | 9.4 | 501 |
| 3 | Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175. | 3.8 | 336 |
| 4 | Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. <i>Annals of Neurology</i> , 2011, 70, 897-912. | 2.8 | 314 |
| 5 | Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405. | 3.7 | 281 |
| 6 | Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078. | 1.1 | 166 |
| 7 | Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298. | 3.7 | 162 |
| 8 | Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746. | 1.4 | 148 |
| 9 | Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435. | 2.8 | 143 |
| 10 | Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617. | 3.7 | 140 |
| 11 | Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211. | 1.5 | 138 |
| 12 | Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281. | 4.9 | 134 |
| 13 | The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. <i>Human Molecular Genetics</i> , 2010, 19, 2134-2143. | 1.4 | 128 |
| 14 | Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686. | 1.1 | 122 |
| 15 | Multifocal motor neuropathy. <i>Neurology</i> , 2007, 69, 1680-1687. | 1.5 | 111 |
| 16 | Incidence and prevalence of NMOSD in Australia and New Zealand. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 632-638. | 0.9 | 108 |
| 17 | Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443. | 3.7 | 94 |
| 18 | Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137. | 0.9 | 76 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522. | 1.4 | 73 |
| 20 | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468. | 0.9 | 71 |
| 21 | Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890. | 2.8 | 67 |
| 22 | Data quality evaluation for observational multiple sclerosis registries. <i>Multiple Sclerosis Journal</i> , 2017, 23, 647-655. | 1.4 | 64 |
| 23 | Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349. | 0.9 | 63 |
| 24 | The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982. | 1.4 | 56 |
| 25 | A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e13454. | 1.1 | 55 |
| 26 | Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643. | 3.7 | 54 |
| 27 | Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797. | 1.5 | 54 |
| 28 | A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5644-5654. | 1.4 | 53 |
| 29 | Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90. | 1.4 | 52 |
| 30 | The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease. <i>Clinical Immunology</i> , 2014, 151, 16-24. | 1.4 | 49 |
| 31 | Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203. | 0.9 | 49 |
| 32 | Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491. | 1.7 | 43 |
| 33 | Polymorphisms in the Receptor Tyrosine Kinase MERTK Gene Are Associated with Multiple Sclerosis Susceptibility. <i>PLoS ONE</i> , 2011, 6, e16964. | 1.1 | 42 |
| 34 | The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. <i>PLoS ONE</i> , 2013, 8, e59694. | 1.1 | 38 |
| 35 | CSF hypotension: A review of its manifestations, investigation and management. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 39-43. | 0.8 | 38 |
| 36 | The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310. | 0.9 | 37 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652. | 1.4 | 37 |
| 38 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171. | 1.4 | 36 |
| 39 | Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626. | 1.4 | 36 |
| 40 | Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99. | 0.3 | 35 |
| 41 | Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243. | 0.9 | 35 |
| 42 | Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661. | 1.1 | 35 |
| 43 | The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532. | 1.4 | 34 |
| 44 | Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739. | 2.8 | 34 |
| 45 | Late effects of oxaliplatin-induced peripheral neuropathy (LEON)â€“cross-sectional cohort study of patients with colorectal cancer surviving at least 2Âyears. <i>Supportive Care in Cancer</i> , 2015, 23, 861-869. | 1.0 | 33 |
| 46 | Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413. | 3.7 | 32 |
| 47 | Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276. | 1.4 | 30 |
| 48 | Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318. | 0.9 | 28 |
| 49 | Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. <i>Frontiers in Neurology</i> , 2020, 11, 537. | 1.1 | 27 |
| 50 | Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480. | 1.1 | 26 |
| 51 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756. | 3.7 | 24 |
| 52 | Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season. <i>Multiple Sclerosis Journal</i> , 2014, 20, 675-685. | 1.4 | 23 |
| 53 | Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. <i>Multiple Sclerosis Journal</i> , 2021, 27, 465-474. | 1.4 | 23 |
| 54 | Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1847-1856. | 0.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Neuromyelitis optica (Devic's disease) in a patient with syphilis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 268-271. | 1.4 | 20 |
| 56 | Resequencing and fine-mapping of the chromosome 12q13-14 locus associated with multiple sclerosis refines the number of implicated genes. <i>Human Molecular Genetics</i> , 2013, 22, 2283-2292. | 1.4 | 20 |
| 57 | Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407. | 4.5 | 20 |
| 58 | Parkinsonism and dementia due to gliomatosis cerebri mimicking sporadic Creutzfeldt-Jakob disease (CJD). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 283-284. | 0.9 | 19 |
| 59 | Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1857-1865. | 0.8 | 19 |
| 60 | A novel mitochondrial DNA deletion producing progressive external ophthalmoplegia associated with multiple sclerosis. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1318-1324. | 0.8 | 18 |
| 61 | Identity-by-Descent Mapping to Detect Rare Variants Conferring Susceptibility to Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e56379. | 1.1 | 18 |
| 62 | Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19. | 0.9 | 17 |
| 63 | The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , 2020, 267, 1431-1443. | 1.8 | 17 |
| 64 | Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1835-1846. | 0.8 | 15 |
| 65 | Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370. | 1.7 | 12 |
| 66 | A Neuroethics Framework for the Australian Brain Initiative. <i>Neuron</i> , 2019, 101, 365-369. | 3.8 | 11 |
| 67 | Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766. | 1.4 | 11 |
| 68 | Muscle-specific kinase antibody positive myasthenia gravis and multiple sclerosis co-presentation: A case report and literature review. <i>Journal of Neuroimmunology</i> , 2013, 264, 130-133. | 1.1 | 10 |
| 69 | Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 301-308. | 1.0 | 10 |
| 70 | A new era in the treatment of multiple sclerosis. <i>Medical Journal of Australia</i> , 2015, 203, 139-141. | 0.8 | 10 |
| 71 | Relapsing encephalopathy with headache: an unusual presentation of isolated intracranial neurosarcoidosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 770-771. | 0.9 | 8 |
| 72 | The effectiveness of natalizumab vs fingolimod—A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012. | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232. | 2.7 | 8 |
| 74 | MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 722237. | 1.1 | 8 |
| 75 | A Case of Valproate Induced Hyperammonemic Encephalopathy. <i>Case Reports in Medicine</i> , 2011, 2011, 1-2. | 0.3 | 7 |
| 76 | Relapsing necrotising encephalomyelopathy due to <i>RANBP2</i> mutation. <i>Practical Neurology</i> , 2019, 19, 360-363. | 0.5 | 7 |
| 77 | Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2022, 28, 958-969. | 1.4 | 6 |
| 78 | Speech-activated myoclonus: An uncommon form of action myoclonus. <i>Movement Disorders</i> , 2005, 20, 1120-1126. | 2.2 | 5 |
| 79 | Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019. | 0.5 | 5 |
| 80 | NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. <i>Journal of Neurology</i> , 2022, 269, 836-845. | 1.8 | 5 |
| 81 | Flow cytometry identifies an early stage of platelet apoptosis produced by agonists of the P2X1 and P2X7 receptors. <i>Platelets</i> , 2022, 33, 621-631. | 1.1 | 5 |
| 82 | Clinical, electrophysiological and genetic features of a large Australian family with paramyotonia congenita. <i>Medical Journal of Australia</i> , 2009, 190, 456-456. | 0.8 | 3 |
| 83 | Clinical, electrophysiological and genetic features of a large Australian family with paramyotonia congenita. <i>Medical Journal of Australia</i> , 2009, 190, 334-336. | 0.8 | 3 |
| 84 | EXPOSURE TO INTERFERON- β THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A17.2-A17. | 0.9 | 2 |
| 85 | The Northern Territory Medical Program “growing our own in the NT. <i>Rural and Remote Health</i> , 2019, 19, 4671. | 0.4 | 2 |
| 86 | Response to treatment in NMOSD: the Australasian experience. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 58, 103408. | 0.9 | 0 |